Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world adjuvant pyrotinib in HER2-positive early breast cancer
ChiCTR2100045712Phase 4Recruiting
- Sponsor
- Affiliated Hospital of Youjiang Medical College for Nationalities
- Start
- May 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of pyrotinib in breast cancer, sponsored by Affiliated Hospital of Youjiang Medical College for Nationalities. Primary endpoint: Disease-free survival time. Started May 2021; status: recruiting.
02
Drugs
pyrotinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2100045712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100045712.